Bailard’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Bailard’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-57,000	Closed	-$1.67M	–	257
2015 Q1	$1.67M	Buy	57,000 +23,000	+68%	+$540K	0.23%	77
2014 Q4	$630K	Hold	34,000	–	–	0.09%	131
2014 Q3	$595K	Hold	34,000	–	–	0.09%	121
2014 Q2	$680K	Hold	34,000	–	–	0.1%	108
2014 Q1	$648K	Hold	34,000	–	–	0.1%	111
2013 Q4	$565K	Sell	34,000 -34,000	-50%	-$581K	0.09%	121
2013 Q3	$1.03M	Buy	+68,000	New	+$668K	0.2%	91

Other funds holding MRTX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Bailard's MRTX Position: Q2 2015 in Review

Bailard sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2015, closing a stake of 57,000 shares — an estimated $1.67M sold.

Bailard first reported a position in MRTX in Q3 2013 and held it in 7 quarters. The position peaked at $1.67M in Q1 2015. 66 funds tracked by Wall St. Rank hold MRTX as of Q2 2015.

Bailard reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2015 after selling out during the quarter.
Bailard sold 57,000 Mirati Therapeutics, Inc. Common Stock shares in Q2 2015, an estimated $1.67M.
Bailard first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2013 and held it in 7 quarters.
Bailard's Mirati Therapeutics, Inc. Common Stock position peaked at $1.67M in Q1 2015.
66 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2015.

Based on Bailard's 13F filing for Q2 2015, filed 6 Aug 2015.